Transaction designed to drive American Bitcoin’s capital markets access and growth trajectoryMIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases such as Bitcoin mining and high-performance computing, today announced that its majority-owned subsidiary, American Bitcoin, has entered into a definitive merger agreeme ...

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three months ended March 31, 2025. Production Strong quarterly production of 47,817 ounces gold equivalent (“AuEq”)(1) or 45,735 oz gold, 1,141,379 lbs copper and 34,085 oz silver, achieving the second highest quarterly production on record. Production exceeded budget and delivered a 74% increase from Q1 2024.Net of by-product credit ...

Peter M. Neupert, Fortrea’s Lead Independent Director, will serve as Interim CEO as Thomas Pike steps downDURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea’s Chief Executive Officer and as Chairman of its Board. Fortrea’s Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 1 ...

MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSX.V: FPC) ("Falco" or the "Corporation") is pleased to announce that it has responded to all questions and comments requested by the Direction de l'évaluation environnementale ("DEE") des projets industriels et miniers on February 27, 2025 (the "Correspondence"), as more fully described in Falco's press release dated March 3, 2025. The responses, commitments, and explanatory letter submitted (the "Responses") follow the meetings and clarific ...

Core Insights - CytomX Therapeutics announced positive interim clinical results for CX-2051, an EpCAM-directed antibody-drug conjugate (ADC) for advanced colorectal cancer (CRC), highlighting its strategic importance for the company [3][7] - The company has initiated dose expansions for CX-2051 at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, with a Phase 2 study planned for the first half of 2026 [7][3] - Financial results for Q1 2025 show total revenue of $50.9 million, an increase from $41.5 million in Q1 2024, driven by collaborations with Bristol Myers Squibb and Amgen [9][10] Pipeline Program Updates - CX-2051 is currently in a Phase 1 dose escalation study, with an update on data from at least 70 patients expected by Q1 2026 [7] - CX-801, a PROBODY interferon alpha-2b, is also in development, with initial Phase 1a translational data expected in the second half of 2025 [7][5] - The company is focusing on combination therapy with CX-801 and KEYTRUDA, aiming to initiate this in 2025 [7] Financial Overview - As of March 31, 2025, the company reported cash, cash equivalents, and investments totaling $79.9 million, down from $100.6 million at the end of 2024 [8] - Total operating expenses for Q1 2025 were $28.3 million, a decrease from $29.8 million in Q1 2024, with R&D expenses at $18.9 million, down from $22.1 million [10][11] - The net income for Q1 2025 was $23.5 million, compared to $13.8 million in Q1 2024, reflecting improved operational efficiency [18]

Core Insights - CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC) [2][3] - The study demonstrated a 28% confirmed response rate and a median progression-free survival of 5.8 months [1][13] - The company plans to initiate a Phase 2 study in the first half of 2026 [1][13] Patient Characteristics - A total of 25 advanced metastatic CRC patients were treated, with a median of 4 prior lines of therapy [6] - 64% of patients had liver metastases, 64% had KRAS mutations, and 96% were microsatellite stable [6] Efficacy Results - 28% of patients (5 out of 18) achieved confirmed partial responses according to RECIST v1.1 [1][6] - At the highest dose of 10 mg/kg, 43% of evaluable patients (3 out of 7) achieved confirmed partial responses [1][6] - The Disease Control Rate was 94% across the three dose groups [6] Safety Results - CX-2051 was generally well-tolerated with no dose-limiting toxicities observed [1][13] - Most treatment-related adverse events were Grade 1 or Grade 2, with common events including diarrhea, nausea, and fatigue [13] Development Plans - Dose expansions have been initiated at doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W, with 20 patients expected to be enrolled at each level [13] - Additional Phase 1 data updates are anticipated by Q1 2026, and combination studies in earlier lines of CRC may begin in 2026 [13]

Core Insights - The report by 21Shares highlights Solana's emergence as a leading blockchain infrastructure for next-generation finance, emphasizing its ultra-high speed, near-zero fees, and expanding ecosystem [2][3] - Solana processes over 3,000 transactions per second with transaction fees consistently below $0.01, and during peak activity in January, it surpassed $364 billion in on-chain volume, matching Nasdaq's throughput [3] - Major integrations with companies like Visa, Shopify, and PayPal, along with innovations such as Solana Blinks and the Saga smartphone, position Solana as a foundational layer for the future internet [3] Company Overview - 21Shares is a prominent issuer of cryptocurrency exchange-traded products (ETPs) and aims to bridge traditional finance with decentralized finance, having launched the first physically-backed crypto ETP in 2018 [6] - The company offers the 21Shares Solana Core Staking ETP (ticker: CSOL), which allows investors to gain exposure to Solana with a management fee of 0.35% and benefits from staking rewards [4] Competitive Analysis - The report includes a detailed comparison of Solana with competitors like Ethereum, Sui, and TON, along with sector analyses of Solana's growing ecosystem, including DePIN, AI agents, and DeFi innovations [8] - A comprehensive valuation framework is provided to assess whether Solana is undervalued relative to its peers, along with insights into its role in a diversified crypto portfolio [8]

Core Insights - Apogee Therapeutics is advancing its clinical pipeline with significant progress in trials for its lead product APG777, targeting atopic dermatitis and asthma, with key data readouts expected in 2025 and 2026 [1][2][8] Pipeline Progress - The Phase 2 APEX trial of APG777 for atopic dermatitis is actively enrolling, with interim 16-week data from Part A expected in mid-2025 and Part B ongoing [1][2][8] - The first patient has been dosed in a Phase 1b trial of APG777 for mild-to-moderate asthma, with results anticipated in the first half of 2026 [1][8] - APG279, a combination of APG777 and APG990, is set to initiate a Phase 1b head-to-head trial against DUPIXENT in 2025, with readout expected in the second half of 2026 [1][8] Clinical Results - Positive interim results from the Phase 1b trial of APG808 in asthma patients showed rapid and sustained suppression of FeNO, a biomarker for Type 2 inflammation, indicating its potential effectiveness [1][8] - APG990's Phase 1 interim results exceeded trial objectives, suggesting a potential for less frequent dosing of the combination therapy [2][8] Market Research Insights - Recent market research indicates strong interest in APG777, with 96% of patients on biologics likely to switch to it, and 80% of physicians likely to prescribe it to new patients [3][4][5] - The AD biologic market is experiencing rapid growth, with a 23% increase in total prescriptions year-to-date, positioning APG777 favorably to capture market share [4][6] Financial Position - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $681.4 million, sufficient to fund operations into Q1 2028 [1][8] - Research and development expenses for Q1 2025 were $46.4 million, up from $28.7 million in Q1 2024, reflecting the advancement of the clinical pipeline [8][12] Upcoming Milestones - The company plans to initiate a Phase 2 trial for eosinophilic esophagitis (EoE) in 2026 and continue its combination approach with APG333 targeting TSLP [8][10] - The first-in-class combination trial of APG279 against DUPIXENT is expected to begin this year, with interim results anticipated in the second half of 2026 [8][10]

Core Insights - U.S. Energy Corporation is focused on becoming a leading provider of non-hydrocarbon industrial gases, with significant progress in its Montana development project [2][3] - The company has a disciplined capital allocation strategy, having divested legacy oil and gas assets, eliminated debt, and returned capital to shareholders through share repurchases [2][8] Financial Performance - For Q1 2025, U.S. Energy reported total hydrocarbon production of approximately 47,008 barrels of oil equivalent (BOE), with oil production accounting for 64% [11] - Total oil and gas sales for Q1 2025 were approximately $2.2 million, a decrease from $5.4 million in Q1 2024, primarily due to divestitures and declining oil prices [11] - The company reported a net loss of $3.1 million, or a loss of $0.10 per diluted share, compared to a net loss of $9.5 million in the same quarter of 2024 [14][24] Operational Developments - U.S. Energy has acquired 24,000 net acres in the Kevin Dome, with the Kiefer Farms well demonstrating helium concentrations of approximately 0.6% and flow rates exceeding 3.2 million cubic feet per day (MMcf/d) [6][10] - The company is set to begin construction of its gas processing plant in July 2025, which will have a processing capacity of 17.0 MMcf/d at a capital cost of approximately $15 million [6][10] Carbon Management Initiatives - The company is projected to permanently sequester approximately 240,000 metric tons of CO₂ annually through its gas injection activities [13] - U.S. Energy has submitted an application for a new Class II injection well, with approval expected in June 2025 [13] Balance Sheet and Liquidity - As of March 31, 2025, U.S. Energy remained entirely debt-free, with approximately $30.5 million in available liquidity [8][9] - The company ended Q1 2025 with a cash balance of $10.5 million, an increase from $7.7 million at the end of 2024 [9][21] Shareholder Returns - U.S. Energy has repurchased approximately 832,000 shares year-to-date, representing about 2.5% of its outstanding shares, reflecting strong alignment with shareholders [15]

Core Insights - Siyata Mobile Inc. has announced a merger with Core Gaming, which has launched the AI COMIC App, aimed at transforming content creation for creators, gamers, and marketers [1][2] - The AI COMIC App utilizes advanced AI models to convert photos and short videos into high-quality visuals, enhancing the creative process [2][3] - The app is designed to democratize studio-grade production capabilities, allowing users to produce content in minutes rather than weeks [3][5] Company Overview - Siyata Mobile Inc. specializes in mission-critical Push-to-Talk over Cellular handsets and accessories, serving various sectors including emergency services and enterprises [7][8] - Core Gaming is an international AI-driven mobile games developer, having developed over 2,100 games and achieving over 780 million downloads globally [12] Product Features - AI COMIC offers a suite of tools including an AI Comic Video Generator, Portrait & Avatar Creator, and various animation and scene design tools [4][9][10] - The platform is supported by a proprietary Compute Pool System that optimizes AI workloads in real-time, enhancing efficiency and cost management [5][10] Future Vision - Core Gaming envisions AI COMIC as a creative partner that evolves with its users, aiming to expand its storytelling capabilities and streamline content deployment across various platforms [6][10] - The company is focused on capturing a significant share of the market by catering to the needs of AAA game studios, digital marketers, and independent creators [6]